Publication:
A case of Cauda Equina syndrome in a leukemic patient due to intrathecal methotrexate

dc.contributor.authorsAteşoǧlu E.B., Tuǧlular T.F., Adigüzel C., Kaygusuz I., Noyan F., Çetiner M., Bayik M.
dc.date.accessioned2022-03-28T14:54:16Z
dc.date.accessioned2026-01-11T11:36:44Z
dc.date.available2022-03-28T14:54:16Z
dc.date.issued2007
dc.description.abstractThe leukemias may cause neurologic dysfunction through either direct invasion of the nervous system or indirectly through cytopenias, or it may occur as a result of the necessarily vigorous treatment programs for leukemia. We report here a 24-year-old acute lymphoblastic leukemia patient who in her second cycle of hyper-CVAD chem therapy regimen (high-dose Ara-C and high-dose methotrexate) received intrathecal methotrexate and two days afterwards was diagnosed as having Cauda Equina syndrome (CES). A lumbo-sacral MRI imaging with gadolinium was performed and there was a remarkable enhancement in the Cauda Equina region, suggesting either leukemic involvement or a type of neurologic complication associated with intrathecal methotrexate treatment. To rule out leukemic involvement, a lumbar puncture was performed and the CSF was free of leukemic cells. There are cases of CES developing after spinal anesthesia reported in the literature, but this is the first report of CES due to intrathecal methotrexate. © Turkish Society of Hematology.
dc.identifier.issn13007777
dc.identifier.urihttps://hdl.handle.net/11424/256115
dc.language.isoeng
dc.relation.ispartofTurkish Journal of Hematology
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAcute lymphoblastic leukemia
dc.subjectCauda Equina syndrome
dc.subjectComplication
dc.subjectIntrathecal methotrexate
dc.titleA case of Cauda Equina syndrome in a leukemic patient due to intrathecal methotrexate
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage31
oaire.citation.issue1
oaire.citation.startPage28
oaire.citation.titleTurkish Journal of Hematology
oaire.citation.volume24

Files